Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00429091 · ClinicalTrials.gov registry record · Phase 2
A Dose-Ranging Study of the Efficacy of ABT-894 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
A Phase 2 study, sponsored by Abbott.
- Completed
- Registry status
- Phase 2
- Development phase
- 243
- Enrollment target
NCT00429091: Completed Phase 2 study, sponsored by Abbott.
NCT00429091 is a Phase 2 study that has completed, run by Abbott. The registered enrollment target is 243 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (83% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00429091, a Phase 2 study, has completed, sponsored by Abbott.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 243 participants
- Enrollment target
Study Summary
A Dose-Ranging Study of the Efficacy of ABT-894 in Adults with Attention-Deficit/Hyperactivity Disorder (ADHD)
Interventions
- DRUG placebo
- DRUG atomoxetine
- DRUG ABT-894
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 243 participants |
| Start Date | 2007-01 |
| Phase | Phase 2 |
What the finished NCT00429091 record still lists
NCT00429091 is an interventional study that assigns participants to a tested intervention. The registered 243 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (83% higher).
The record links to 0 conditions, and to 3 interventions - of which placebo is the first listed.
NCT00429091 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00429091 about?
NCT00429091 is a clinical study titled "A Dose-Ranging Study of the Efficacy of ABT-894 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)". A Dose-Ranging Study of the Efficacy of ABT-894 in Adults with Attention-Deficit/Hyperactivity Disorder (ADHD)
What is the current status of trial NCT00429091?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 243 participants. The study started on 2007-01.
What interventions are being tested in trial NCT00429091?
The interventions under investigation include: placebo (DRUG), atomoxetine (DRUG), ABT-894 (DRUG).
Who is sponsoring clinical trial NCT00429091?
This trial is sponsored by Abbott, which has 181 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00429091's enrollment target sits among peer trials
243 236th of 2000 higher than 1,764 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06253871 · 243 participants · Phase 1
A Phase 1/1b Study of IAM1363 in HER2 Cancers
- NCT06289491 · 243 participants · NA
A Trial of Hydrus Microstent Versus Goniotomy
- NCT06536296 · 243 participants · NA
The Impact of Music Medicine on Preterm Brain Development and Behavior
- NCT06907615 · 243 participants · Phase 2
A Phase II Clinical Study to Evaluate HLX43 in Subjects With Advanced Non-small Cell Lung Cancer (NSCLC)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia